---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020699"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T19:00:59.316256+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology Q3 net loss $27.7M, expands Pfizer ADC licensing deal

## Summary
- Net loss of $27.7M ($0.85 per share) for Q3 2022 vs. $14.2M ($8.96 per share) in Q3 2021.
- Cash and cash equivalents (incl. restricted) $200.0M as of Sept 30, 2022; expected to fund operations into end of 2024.
- Expanded worldwide licensing deal with Pfizer for exclusive rights to Pfizer’s ADC technology platform and toolkit.
- First multi-target sublicensing agreement executed with a stealth ADC company under the new Pfizer arrangement.
- IND filings for PYX-106 and PYX-201 on track by end of 2022.

## SEC filing metadata
- accession: 0000950170-22-020699
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017022020699/0000950170-22-020699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017022020699/pyxs-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020699
- JSON: https://secwatch.observer/filing/0000950170-22-020699.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020699.txt

## Key facts
- Earnings Releases
  Pyxis Oncology, Inc. reported three months ended September 30, 2022 results: net income $27.7 million, EPS $(0.85) per common share.
  - Period: three months ended September 30, 2022
  - Net income: $27.7 million
  - EPS: $(0.85) per common share
  - Result: reported results
  source text: Net loss was $27.7 million, or $(0.85) per common share, for the three months ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017022020699/0000950170-22-020699-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.